<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461213</url>
  </required_header>
  <id_info>
    <org_study_id>CHM09/01</org_study_id>
    <secondary_id>2009-014617-27</secondary_id>
    <nct_id>NCT01461213</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Blindness Caused by Choroideremia</brief_title>
  <official_title>An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - Primary objective: To assess the safety and tolerability of the AAV.REP1 vector,
      administered at two different doses to the retina in 12 patients with a diagnosis of
      choroideremia.

      - Secondary Objective: To identify any therapeutic benefit as evidenced by a slowing down of
      the retinal degeneration assessed by functional and anatomical methods in the treated eye
      compared to the control eye 24 months after gene delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description may be found in the following scientific publication:

      Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2
      clinical trial, The Lancet, Volume 383, Issue 9923, Pages 1129 - 1137 (29 March 2014).

      Links: www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62117-0/abstract ;
      http://dx.doi.org/doi:10.1016/S0140-6736(13)62117-0
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Best corrected visual acuity, following cataract surgery if indicated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microperimetry, OCT and fundus autofluorescence</measure>
    <time_frame>24 months</time_frame>
    <description>Structure function correlations at the margins of the retinal degeneration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAAV2.REP1</intervention_name>
    <description>Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <other_name>Adeno-associated viral vector</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study,

          -  Male aged 18 years or above,

          -  Diagnosed with choroideraemia and in good health,

          -  Active disease with SLO changes visible within the macula region,

          -  Willing to allow his or her General Practitioner and consultant, if appropriate, to be
             notified of participation in the study,

          -  Vision at least 6/60 or better in the study eye.

        Exclusion Criteria:

          -  Female and child participants (under the age of 18),

          -  Men unwilling to use barrier contraception methods, if relevant,

          -  Previous history of retinal surgery or ocular inflammatory disease (uveitis),

          -  Grossly asymmetrical disease or other ocular morbidity which might confound use of the
             fellow eye as a long-term control,

          -  Any other significant disease or disorder which, in the opinion of the Investigator,
             may either put the participants at risk because of participation in the study, or may
             influence the result of the study, or the participant's ability to participate in the
             study,

          -  Participants who have participated in another research study involving an
             investigational product in the previous 12 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E MacLaren, MB ChB DPhil</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oxford, Oxford Radcliffe Hospitals NHS Trust and Moorfields Eye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel C Seabra, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew R Webster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Institute of Ophthalmology and Moorfields Eye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan M Downes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Graeme C Black, MB BCh DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester and Central Manchester University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew J Lotery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southampton and Southampton University Hospitals Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Len W Seymour, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanya Tolmachova, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Unit, Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tapetoretinal degeneration, choroideraemia, X-linked</keyword>
  <keyword>retinitis pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

